Physician profile
Elias Reichel
NPI 1053376939
$673,647.60
in general payments reported to CMS, 2019-2025
22 companies · $234 in 2025
The $234 reported for 2025 was less than what a typical Uveitis and Ocular Inflammatory Disease provider received nationally (typical 2025 total: $471).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $114K · 2020: $69K · 2021: $30K · 2022: $119K · 2023: $214K · 2024: $128K · 2025: $234.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Royalty Or License: $339K · Consulting Fee: $2,775 · Food and Beverage: $358.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Royalty Or License | $338,580.89 |
| Consulting Fee | $2,775.00 |
| Food and Beverage | $357.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Thea Pharma INC. | $440,198.60 | 2022-2024 | Akten |
| Regeneron Healthcare Solutions, INC. | $184,382.13 | 2019-2022 | |
| Spark Therapeutics, INC. | $15,940.73 | 2019-2021 | |
| Janssen Research & Development, LLC | $12,658.20 | 2020-2021 | |
| Eyepoint US, INC. | $5,797.14 | 2019-2023 | |
| Novartis Pharmaceuticals Corporation | $5,469.75 | 2019-2020 | |
| F. Hoffmann-La Roche Ag | $2,702.17 | 2019 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $1,702.68 | 2020 | |
| Cardinal Health 108 LLC | $1,575.00 | 2020 | |
| Thrombogenics, INC. | $1,250.00 | 2020 | |
| Ocular Therapeutix, INC. | $1,033.73 | 2019-2020 | |
| Alimera Sciences, INC. | $271.02 | 2019-2022 | |
| Neurotech Pharmaceuticals, INC. | $233.78 | 2025 | |
| Alcon Vision LLC | $130.00 | 2019 | |
| Regeneron Pharmaceuticals, INC. | $124.15 | 2023 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $88.80 | 2019-2020 | |
| Genentech USA, INC. | $37.85 | 2019-2022 | |
| Apellis Pharmaceuticals, INC. | $29.30 | 2022 | |
| Abbvie INC. | $22.57 | 2022 |
3 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Elias Reichel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.